Jul 1, 2020
June 30, 2020:
Fire Tertiary, Snapper, Filigree.
Shokubai of Foa's
seen from Peru
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from Canada
seen from Malaysia
seen from United States
seen from United States
seen from United States
seen from United States
seen from Australia
seen from United States
seen from United States
seen from South Korea
seen from United States
seen from Argentina
seen from Malaysia
seen from United States
June 30, 2020:
Fire Tertiary, Snapper, Filigree.
Shokubai of Foa's
Nippon Shokubai breaks ground for new API synthesis facility
Nippon Shokubai Co Ltd held a ground-breaking ceremony on, for the construction of a facility of active pharmaceutical ingredient (API) synthesis. The construction will be completed in December 2018.
Purpose of investment
In the current long-term business plan “Reborn Nippon Shokubai 2020” started in 2014 and the 2nd medium-term Business Plan “Reborn Nippon Shokubai 2020 NEXT” started in 2017, Nippon Shokubai has a plan to open up a health and medical business field as one of the new business domains. Targeting the peptide drugs, nucleic-acid drugs and DDS where market growth is expected, Nippon Shokubai is establishing a drug development support business that provides customers a consistent service from drug discovery & clinical studies to contract manufacturing.
In order to establish a business base on these promising areas, Nippon Shokubai keeps on not only seeking out chances of business partnerships with innovative technical resources outside the company but also studying a feasibility of establishing function of manufacturing these kinds of APIs.
Read More: Nippon Shokubai breaks ground for new API synthesis facility